New Atropos–Arcadia partnership to drive value-based personalized clinical decision-making by democratizing access to bespoke real-world evidence

New Atropos–Arcadia collaboration to add Atropos on-demand personalized real-world evidence generation to Arcadia data platform and to expand Atropos Evidence Network with Arcadia real-world data.

Atropos Health, pioneer provider of on-demand, personalized real-world evidence (RWE), announced on January 5, 2024 that it has forged a new collaboration with Arcardia, a leading healthcare real-world data (RWD) platform company. The partnership will see Arcadia’s extensive longitudinal RWD incorporated into the Atropos Evidence Network to be leveraged for RWE studies by their life sciences partners, and the Atropos Health portfolio of cutting-edge RWE generating applications made accessible to Arcadia’s data provider customers, to drive high-value, low-cost whole person care for patients based on their unique physiology.

Atropos Health’s mission is to transform health care with timely, relevant RWE – they provide bespoke evidence on-demand from RWD to close evidence gaps in health care and life sciences, aiming to elevate clinical outcomes, accelerate research, and drive operational efficiency.

“A critical component of value-based care is the optimization of clinical decision-making where existing published evidence falls short,” said Brigham Hyde, CEO and Co-Founder of Atropos Health. “This optimization is what Atropos Health delivers across our products, and we’re proud to bring the high-quality data Arcadia is known for into the Atropos Evidence Network. This collaboration further enables healthcare providers to generate novel peer-reviewed evidence rapidly to make data-driven decisions on optimal clinical guidelines, care pathways, and the best interventions to succeed in value-based care and other quality initiatives.”

The Atropos Health suite of pioneering evidence generation applications features the Green Button Informatics Consult Service for which Atropos first became renowned, and newer elements including the CRAFT (Clinical Research Acceleration for Trials) Emulation Toolkit™ and the massive Alexandria™ collection of existing studies. October 2023 saw the addition of Geneva OS™ (Generative Evidence Acceleration Operating System) and ChatRWD™, the first generative artificial intelligence (AI) healthcare application incorporating direct chat-to-database capability.

The new collaboration between Atropos and Arcadia will open up access to the revolutionary, novel on-demand RWE generation. “Arcadia’s collaboration with Atropos Health empowers care organizations to provide high-quality, cost-effective care that helps improve patient outcomes through democratized access to clinical research evidence,” said Michael Meucci, President and CEO of Arcadia. “Integrating Atropos Health’s generative AI capability into Arcadia’s data platform is the latest example of how we’re equipping our customers with plug-and-play access to proprietary and third-party enablers that improve workflows and support value-based performance goals.”